Novel Biological Interaction Found To Explain Blood Vessel Growth To Tumors

March 16, 1999

DURHAM, N.C. -- Duke University Medical Center researchers believe they have answered one of cancer's central enigmas: why some blood vessels are able to grow to, and feed, tumors, while other vessels are not. In the March 16 issue of the Proceedings of the National Academy of Science, the scientists report the blood protein angiostatin, which is known to stop the growth of new blood vessels to tumors, works by depleting the chemical energy that blood vessel cells need to grow.

To do this, angiostatin latches on to and inhibits ATPsynthase, an enzyme that provides chemical energy for the cell. Without that energy, blood vessels cannot grow to the site of a tumor, and without the nutrient supply in blood, tumors cannot grow larger than a pinhead.

Conversely, when unchecked by angiostatin, ATPsynthase provides a generator of sorts to blood vessels so that they can survive in the atmosphere of cell death caused by cancer. Cancer researchers have long wondered how these vessels stay vigorous enough to continue to grow to and feed tumors.

Lead scientists Dr. Sal Pizzo and Tammy Moser said the discovery is "startling" because the ATPsynthase enzyme has never before been found on the surface of endothelial cells, which are the cells that line blood vessels.

In fact, ATPsynthase has not been known to exist outside of a cell body. It has only been found within a mitochondria, a sac-like structure which acts as a cell's chemical powerhouse.

"It was surprising to see ATPsynthase on blood vessel cells because it was never expected there," said Pizzo in an interview. "But it makes perfect biological sense, and it's terribly exciting."

The finding offers both theoretical as well as practical implications, Pizzo said. It offers a novel insight into the body's use of ATPsynthase as "power packs" in situations where energy is depleted. And it suggests a new route to developing drugs that block angiostatin.

"Instead of using the whole angiostatin protein as a drug to stop tumor angiogenesis, as efforts are now underway to do, it may be possible to design a small molecule that will do what angiostatin does -- turn off ATPsynthase," Moser said.

Pizzo added that, in the future, it may be possible to find a molecule that turns on ATPsynthase "in cases where you want new blood vessel growth, such as in heart disease."

Because she led the laboratory investigation, Moser checked, rechecked and expanded her findings over a span of several years to be sure of the conclusions. "A lot of labs might have pulled out and said it was a mistake, but it seemed a very rational explanation worthy of replication," she said.

The discovery is very important because "the ATPsynthase-binding protein may be used as a target to find small molecules, which could mimic angiostatin, but could be taken orally, and perhaps would be easier to manufacture," according to Dr. Judah Folkman, a cancer researcher at Children's Hospital in Boston who pioneered angiostatin research. "If such small molecules are developed, they may also enhance the activity of angiostatin."

Folkman, a member of the National Academy of Sciences, was the scientist who submitted the paper to PNAS, the academy's journal, although he didn't participate in the research.

Working with Pizzo and Moser on the study were Duke researchers Iain Asplin, Jan Enghild and Lorraine Everitt. Their collaborators include Danish researcher Peter Hojrup, and, from Northwestern University Medical School, Sharon Stack, Susan Hubchak and William Schnaper. The study was supported by a research grant from Glaxo Wellcome Inc. Duke University holds the patent rights to the discovery.

The field of angiostatin research grew from the observation that some, but not all, tumors seem to be able to control the spread, or metastasis, of cancer elsewhere in the body.

Cancer physicians have long known that sometimes, when a single large tumor is removed from a patient, subsequent tumors will come back quickly and spread, seeding the body with deadly fast-growing tumors.

A decade ago, Folkman proposed that tumors themselves regulate the growth of blood vessels. One notion was that tumors could produce proteins that would travel through the bloodstream, preventing vessels from growing to any new cancer metastasis. This idea explains what has been observed, although no one understands why a tumor would exert such control, or why only some tumors work in this way.

Folkman's lab later found the substance that inhibits blood vessel growth. It was a small piece of a large and common blood protein called plasminogen, which is involved in blood clotting. He called this protein "angiostatin," and demonstrated it was involved in "anti-angiogenesis" -- stopping the process of new blood vessel growth.

Folkman then showed in animal experiments that injections of the angiostatin protein stopped tumors from growing, and efforts have been underway in the last year to produce a drug for human cancer therapy based on the angiostatin molecule.

Pizzo and Moser set out to study what happened when angiostatin "bound" on the surface of endothelial cells. They looked for where angiostatin's "key" fit into the cellular "lock" that then shut down vessel growth.

Since plasminogen is known to bind to a protein called annexin II on endothelial cells, they expected to find that angiostatin bound to same site. After several years of gathering material and analyzing data, Moser found a different molecule, which she identified by mass spectrometry as ATPsynthase. Moser then tested her findings by introducing an antibody to ATPsynthase that would block the action between angiostatin and endothelial cells. Indeed, she found the antibody blocked angiostatin's ability to inhibit proliferation by 90 percent.

The researchers stressed that while there is still much to learn about how angiostatin regulates blood vessel growth, there are now many new interesting theories to explore.

For example, Pizzo and Moser speculate that blood vessels grow into tumors by capitalizing on the death of cancer cells in the core of tumors due to lack of oxygen.

A tumor is an ever expanding knot of cancer cells, and its central core is often composed of cells that are dying from a lack of oxygen. When cells die, they release a depleted form of chemical fuel called ADP. And it is ADP that the ATPsynthase molecule uses to produce ATP, the body's high energy fuel. So it may be that "vessels are feeding on cell death to grow," Moser said. "This is a very novel strategy."

Folkman added: "Because ATP is necessary for cells to resist conditions of low oxygen, and because the enzyme to produce ATP is situated on the outer surface of endothelial cells, angiostatin, by binding to this enzyme could preferentially inhibit endothelial cells that are in the vascular bed of a tumor, where oxygen would be lower than elsewhere in the body."

Duke University Medical Center

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to